

Supramolecular Nanostructures Formed by Anticancer Drug Assembly

Andrew G. Cheetham,^{†,‡} Pengcheng Zhang,[†] Yi-an Lin,^{†,‡} Lye Lin Lock,[†] and Honggang Cui^{*,†,‡}

[†]Department of Chemical and Biomolecular Engineering, and [‡]Institute for Bionanotechnology (INBT), Johns Hopkins University, Baltimore, Maryland 21218, United States

S Supporting Information

ABSTRACT: We report here a supramolecular strategy to directly assemble the small molecular hydrophobic anticancer drug camptothecin (CPT) into discrete, stable, well-defined nanostructures with a high and quantitative drug loading. Depending on the number of CPTs in the molecular design, the resulting nanostructures can be either nanofibers or nanotubes, and have a fixed CPT loading content ranging from 23% to 38%. We found that formation of nanostructures provides protection for both the CPT drug and the biodegradable linker from the external environment and thus offers a mechanism for controlled release of CPT. Under tumor-relevant conditions, these drug nanostructures can release the bioactive form of CPT and show in vitro efficacy against a number of cancer cell lines. This strategy can be extended to construct nanostructures of other types of anticancer drugs and thus presents new opportunities for the development of self-delivering drugs for cancer therapeutics.

The creation of vehicles for the effective delivery of hydrophobic anticancer drugs to tumor sites has garnered major attention in cancer chemotherapies for several decades.^{1–4} A successful strategy promises immense benefits to cancer sufferers through both the reduction of side effects and a greater treatment efficacy.⁵ Current approaches focus on the use of nanocarriers, whereby the drug's pharmacokinetic properties and biodistribution profiles are manipulated by encapsulation within liposomes, polymeric nanoparticles or micelles,^{6–12} or by conjugation to hydrophilic polymers or inorganic nanomaterials.^{2,13,14} While these methods can be effective, there are concerns regarding the short-term and long-term toxicities arising from the synthetic nanomaterials other than the drug being delivered.¹⁵ Furthermore, there are inherent difficulties in achieving a *quantitative* and *high* drug loading per carrier (typically less than 10%).² Polydispersity, both in terms of polymer length and the amount of drug loaded or conjugated, is a critical issue susceptible to significant batch-to-batch variability. On the other hand, small molecule prodrugs are monodisperse but can be subject to rapid clearance and premature degradation.¹⁶ Recently, the use of drug molecules to promote self-assembly into micellar structures has been reported,^{17–20} however, these systems demonstrated limited tunability in the resulting morphologies and the drug loading content.




Figure 1. Schematic illustration of the designed and synthesized drug amphiphiles (DAs) and control molecules. (a) Self-assembled nanostructures containing the same drug fraction as the individual DA. (b) Three key component parts of the drug amphiphiles studied in this paper: the hydrophobic drug CPT, the Tau- β -sheet-forming peptide, and the buSS biodegradable linker. (c) The synthesized CPT DAs with quantitative drug loadings of 23%, 31%, and 38%. (d) The two synthesized control molecules.

We report here the design of monodisperse, amphiphilic anticancer drugs—which we term *drug amphiphiles* (DAs)—that can spontaneously associate into discrete, stable supramolecular nanostructures with the potential for self-delivery (no additional carriers are needed). Specifically, we conjugated the hydrophobic drug camptothecin (CPT), a DNA-topoisomerase I inhibitor,^{24,25} to a β -sheet-forming peptide sequence derived from the Tau protein²⁶ through the reducible disulfylbutyrate (buSS) linker²⁷ (Figure 1a). This concept of conjugating small molecular hydrophobic units to a short peptide segment to promote new self-assembling features and to achieve new functional properties has been demonstrated by a few laboratories.^{20–23} The drug content was precisely controlled using the two amine functionalities of the amino acid lysine to create branching points that allow the attachment of one, two or four CPT molecules, corresponding to respective drug loadings of 23%, 31% and 38% (Figure 1b). The drug

Received: November 30, 2012

Published: February 4, 2013




Figure 2. TEM characterization illustrating the effect of CPT content on the self-assembled morphology of DA molecules. TEM (a) and cryo-TEM (b) images of long filaments of widths 6.7 ± 1 nm formed by **mCPT-buSS-Tau** in water. TEM (c) and cryo-TEM (d) images of shorter filaments of widths 7.2 ± 1.4 nm formed by **dCPT-buSS-Tau** in water. TEM (e,g,h) and cryo-TEM (f) images of nanotubes of widths 9.5 ± 1 nm formed by **qCPT-buSS-Tau** in water. The cryo-TEM (f) resolution is insufficient to show the tubular nature. The circular shape of the terminal ends (marked with white arrows in (g) and (h)) confirms the tubular structures. Solution concentrations: $50 \mu\text{M}$ for (a), (c), (e), (g), and (h); 1 mM for (b) and (d); $100 \mu\text{M}$ for (e).




Figure 3. Circular dichroism (CD, solid line) and UV-vis (dashed line) spectroscopic analysis of $1 \mu\text{M}$ **mCPT-buSS-Tau** (a), $1 \mu\text{M}$ **dCPT-buSS-Tau** (b), and $1 \mu\text{M}$ **qCPT-buSS-Tau** (c) in 10 mM sodium phosphate at 37°C . Release study of $2 \mu\text{M}$ DA and control molecules in the presence and absence of 10 mM glutathione (GSH) in 10 mM sodium phosphate (d). Comparison of **mCPT-buSS-Tau** release kinetics at $2 \mu\text{M}$ and $20 \mu\text{M}$ (e). Release experiments were performed in triplicate, and values are given as mean \pm s.d. (Key: mono = **mCPT-buSS-Tau**, di = **dCPT-buSS-Tau**, quad = **qCPT-buSS-Tau**, maleimide = **mCPT-mal-Tau**, (+) or (–) indicates the presence or absence of 10 mM glutathione, respectively). Schematic illustration of the proposed release mechanism showing the effect of self-assembly on the susceptibility of the DAs to degradation (f).

conjugates were synthesized by reaction of the appropriate cysteine-containing Tau peptide with the activated disulfide **CPT-buSS-Pyr** in DMSO, followed by purification to $>99\%$ homogeneity by reversed-phase HPLC (Supporting Information [SI], Figures S1–S4). A nonreducible CPT-containing DA, **mCPT-mal-Tau**, and an octanoic acid-functionalized peptide, **C₈-Tau**, were also synthesized to act as control molecules (Figures 1c, and Figures S5–S6 in SI). The identity and purity for all the studied molecules were confirmed using mass spectrometry and analytical HPLC, respectively.

Transmission electron microscopy (TEM) and cryogenic TEM (cryo-TEM) imaging reveals that all the CPT drug amphiphiles assemble into filamentous nanostructures in water (Figure 2). At $50 \mu\text{M}$, **mCPT-buSS-Tau** was observed to form filaments of widths 6.7 ± 1 nm (Figure 2a) and lengths on the scale of a few micrometers, and **dCPT-buSS-Tau** forms

nanofibers of widths 7.2 ± 1.4 nm (Figure 2c) that were predominantly shorter than those formed by **mCPT-buSS-Tau**. The diameters of these nanofibers are approximately twice that of the expected molecular length (~ 3.5 and 3.8 nm, respectively), indicating a cylindrical packing geometry of core-shell micelles. **qCPT-buSS-Tau** forms even shorter fibrous nanostructures ($<1 \mu\text{m}$) of widths 9.5 ± 1 nm (TEM images e, g, and h of Figure 2 and Figure S7 in SI), with a dark centerline throughout all the observed nanostructures. This dark centerline is due to the deposition of the negative staining agent, uranyl acetate, and suggests the structures possess a hollow core that may have collapsed during TEM sample preparation. The image features observed here are remarkably similar to those of the tobacco mosaic virus²⁸ and other structures in the literature that are known to have a tubular morphology.^{29,30} The circular shape of their terminal ends

further confirms the tubular morphology (images g and h of Figure 2 and Figure S7 in SI). The comparable value of the nanotube wall thickness to the molecular length (4 nm vs 4.1 nm) implies that the molecules are packed in a monolayered rather than bilayered fashion. These results demonstrate that the incorporation of different numbers of CPT units into the drug amphiphiles can tune both the drug loading content and the assembly morphologies.

Clearly, the one dimensionality (1D) is linked to the β -sheet forming Tau peptide that provides a directional, intermolecular hydrogen bonding.²⁶ The C₈-Tau control molecule without any CPT unit also forms similar filaments in water (Figure S8 in SI), confirming the leading role of Tau peptides in these 1D assemblies. The β -sheet secondary structure was confirmed for each DA molecule by the observation of a negative signal around the 220 nm region of the circular dichroism (CD) spectra (Figure 3a–c).^{22,31}

We speculate that the morphological differences of the observed nanostructures are rooted in the number of CPT molecules within the conjugates. We therefore performed spectroscopic studies to investigate the CPT packing within the assemblies. We found that the CD spectra of aqueous solutions of both **mCPT-buSS-Tau** (Figure 3a) and **dCPT-buSS-Tau** (Figure 3b) display strong signals in the CPT absorption regions at 250 nm and between 330 and 400 nm, in accordance with the visible absorptions in the corresponding UV–vis spectra. No CPT absorption signals, however, were observed for the CPT conjugates dissolved in DMSO where these conjugates are expected to exist in a monomeric form (Figure S9 in SI). Since CD measures absorption differences between left and right circularly polarized light, these results clearly suggest a chiral packing of the CPT moieties in the aggregated form, and the greater amplitude of the diCPT conjugate CD signal indicates a stronger degree of chiral arrangement. Surprisingly, **qCPT-buSS-Tau** exhibits two bisignate CD signals centered at 265 and 366 nm and a strong positive signal at 389 nm (Figure 3c). This bisignate Cotton effect has been frequently reported in aggregated π -conjugated systems, resulting from exciton coupling between two adjacent chromophores in a chiral orientation.^{32,33} Hence, the observed CD signals are indicative of a strong exciton coupling between neighboring CPT quinoline rings of the same or adjacent conjugates. The positive sign of the couplet signal at the highest wavelength suggests a positive chirality and a right-handed helical arrangement of the CPT molecules within the nanotubes. The strong interactions among CPT units might play a crucial role for formation of the observed nanotube morphology, although the exact mechanism is not clear and requires further evaluation.

The short-term stability of the nanostructures formed by the studied molecules toward dilution was probed using a fluorescence method based on static quenching of the CPT fluorophore (SI S2.3.1). At short equilibration times (2 min), a dilution study showed dissociation occurring around 207 nM, 74 nM and 53 nM for **mCPT-buSS-Tau**, **dCPT-buSS-Tau**, and **qCPT-buSS-Tau**, respectively (Figure S10 in SI). The greater stability associated with higher CPT content is expected, likely a result of an increasing hydrophobicity in combination with possible π – π associative interactions among the CPT units. Given the hydrophobic nature of CPT and the preference that the Tau peptide has for parallel β -sheet formation,²⁶ it is reasonable to assume that the CPT segments are buried in the cores of the assembled nanostructures, thereby preventing CPT

from undergoing undesired conversion to the inactive acid form. Indeed, the fluorescence spectra of these DAs show an emission maximum in the 430 nm region (Figure S11 in SI), consistent with the CPT having the closed lactone form rather than the open carboxylate which emits at 446 nm.^{14,24,34}

Given the core–shell micellar nature of these assemblies, it would be expected that assembly into nanostructures would shield the degradable linker from the external environment and thus offer a mechanism for the controlled release of bioactive CPT.³⁵ The release profiles of the DAs were assessed by incubation of 2 μ M solutions at 37 °C in 10 mM sodium phosphate in the presence and absence of 10 mM glutathione (GSH), respectively (Figure 3d). Glutathione is a cancer-relevant reducing agent that can degrade the designed buSS linker to release CPT.³⁶ In the absence of GSH, hydrolytic cleavage of the CPT ester bond is responsible for any observed release. All DAs were seen to exhibit a steady rate of release, with no sudden burst kinetics. It is evident that for molecules with the reducible linkers CPT release was faster in the presence of GSH than in its absence. For the nonreducible control DA, **mCPT-mal-Tau**, which is susceptible to hydrolysis of the CPT ester bond only, no significant difference between the two conditions was observed. It is also evident that both **dCPT-buSS-Tau** and **qCPT-buSS-Tau** show an increased resistance to degradation relative to **mCPT-buSS-Tau**. We attribute this to their greater relative stability as the nanostructures formed by **dCPT-buSS-Tau** and **qCPT-buSS-Tau** will have a lesser propensity for disassembly at the concentration studied, with **mCPT-buSS-Tau** existing in more of a monomeric state than assembled. To confirm this effect, we performed experiments studying the degradation of the **mCPT-buSS-Tau** at a higher concentration (20 μ M), where a significant majority of the molecule would be expected to exist in the nanostructure form. Figure 3e supports this idea as the stability toward hydrolytic cleavage (in the absence of GSH) is greatly enhanced, with 95% of the conjugate remaining after 8 h compared with 40% at 2 μ M. A similar, but less pronounced, enhancement is observed in the presence of GSH, with 52% of the conjugate remaining after 8 h at the higher concentration compared with 9% at the lower. These experiments suggest the CPT release mechanism shown in Figure 3f, indicating that the self-assembled nanostructures can serve as reservoirs to provide a consistent supply of CPT conjugate monomers that can be quickly converted to bioactive CPT in the presence of GSH.

We evaluated the in vitro toxicity of the designed DAs against a number of cancer cell lines (Figure 4). Human MCF-7 breast cancer cells and two rat gliosarcoma lines (9L and F98L) were initially tested with varying concentrations of conjugates in order to determine a dose–response relationship (Figure 4 and Figure S12a in SI). For all three cell lines the general trend is clear, with the reduction-sensitive DAs exerting a greater cytotoxic effect than the nonsensitive **mCPT-mal-Tau**. Although we cannot rule out the possibility of extracellular hydrolysis followed by diffusion of released CPT into cells, the marked difference between the buSS and mal-linked conjugates suggests that reductive degradation by GSH is dominant and mainly responsible for the observed toxicity. The C₈-Tau control experiment reveals that the Tau peptide alone presents no cytotoxic effects at the concentrations studied. Of the three DAs, **dCPT-buSS-Tau** was consistently observed to be the most effective at inhibiting the proliferation of cancer cells followed by **qCPT-buSS-Tau** and then **mCPT-buSS-Tau**.




Figure 4. In vitro dose–response relationship study of the DA molecules against human MCF-7 breast cancer (a) and rat 9L gliosarcoma (b) cells. All cancer cells were incubated with the appropriate DA molecules for 48 h and cell viability was determined by SRB assay. Data are given as mean \pm s.d. ($n = 3$). The DA concentrations and the calculated IC_{50} values (in parentheses) were normalized with respect to the number of CPT molecules.

Since the CPT drug must enter the cell nucleus to exert its cytotoxic effect, cellular uptake presents an important step in determining the IC_{50} of the designed drug conjugates. One possible explanation for **dCPT-buSS-Tau** having the lowest IC_{50} may be its balanced hydrophobic–hydrophilic ratio allowing for the most efficient translocation of the conjugate into cells. Given the higher potency of **dCPT-buSS-Tau**, a wider range of cancer cell lines were assessed for their response to this DA (b–f of Figure S12 in SI), showing comparable to moderate activity versus CPT.

In this paper, we have reported a strategy to construct discrete drug nanostructures with a high and fixed drug content. We believe this strategy can be extended to fabricate nanostructures of other important anticancer drugs, such as paclitaxel and doxorubicin, and with proper molecular design and fine-tuning of the self-assembly conditions it should be possible to have access to vesicular and spherical morphologies. The use of small molecular anticancer drugs as active molecular building units, not just passive cargoes to be delivered, opens up new opportunities for the development of drug nanostructures that can self-deliver.

■ ASSOCIATED CONTENT

● Supporting Information

Experimental details and figures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

hcui6@jhu.edu

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank Johns Hopkins University (JHU) for the Startup fund, and the NIH for funding A.C. (T-32CA130840) and Y.L. (R25CA153952). We thank the JHU Integrated Imaging Center (IIC) for the use of the TEM facility, and the JHU Department of Chemistry Mass Spectrometry facility for MALDI-ToF analysis (NSF CHE-0840463). We also thank Prof. Kalina Hristova for the use of CD and fluorescence instrumentation.

■ REFERENCES

(1) Peer, D.; Karp, J. M.; Hong, S.; FaroKhzad, O. C.; Margalit, R.; Langer, R. *Nat. Nanotechnol.* **2007**, *2*, 751.

- (2) Duncan, R. *Nat. Rev. Cancer* **2006**, *6*, 688.
 (3) Hoffman, A. S. *J. Controlled Release* **2008**, *132*, 153.
 (4) Euliss, L. E.; DuPont, J. A.; Gratton, S.; DeSimone, J. M. *Chem. Soc. Rev.* **2006**, *35*, 1095.
 (5) Yoo, J. W.; Irvine, D. J.; Discher, D. E.; Mitragotri, S. *Nat. Rev. Drug Discovery* **2011**, *10*, 521.
 (6) Discher, D. E.; Eisenberg, A. *Science* **2002**, *297*, 967.
 (7) Li, S. D.; Huang, L. *Mol. Pharmaceutics* **2008**, *5*, 496.
 (8) Torchilin, V. P. *Nat. Rev. Drug Discovery* **2005**, *4*, 145.
 (9) Hu, C. M. J.; Zhang, L.; Aryal, S.; Cheung, C.; Fang, R. H.; Zhang, L. F. *Proc. Natl. Acad. Sci. U.S.A.* **2011**, *108*, 10980.
 (10) Geng, Y.; Dalhaimer, P.; Cai, S. S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D. E. *Nat. Nanotechnol.* **2007**, *2*, 249.
 (11) Lin, L. Y.; Karwa, A.; Kostelc, J. G.; Lee, N. S.; Dorshow, R. B.; Wooley, K. L. *Mol. Pharm.* **2012**, *9*, 2248.
 (12) Poon, Z.; Lee, J. B.; Morton, S. W.; Hammond, P. T. *Nano Lett.* **2011**, *11*, 2096.
 (13) Liong, M.; Lu, J.; Kovichich, M.; Xia, T.; Ruehm, S. G.; Nel, A. E.; Tamanoi, F.; Zink, J. I. *ACS Nano* **2008**, *2*, 889.
 (14) Cheng, J. J.; Khin, K. T.; Jensen, G. S.; Liu, A. J.; Davis, M. E. *Bioconjug. Chem.* **2003**, *14*, 1007.
 (15) Dobrovolskaia, M. A.; McNeil, S. E. *Nat. Nanotechnol.* **2007**, *2*, 469.
 (16) Huttunen, K. M.; Raunio, H.; Rautio, J. *Pharmacol. Rev.* **2011**, *63*, 750.
 (17) MacKay, J. A.; Chen, M. N.; McDaniel, J. R.; Liu, W. G.; Simnick, A. J.; Chilkoti, A. *Nat. Mater.* **2009**, *8*, 993.
 (18) Shen, Y. Q.; Jin, E. L.; Zhang, B.; Murphy, C. J.; Sui, M. H.; Zhao, J.; Wang, J. Q.; Tang, J. B.; Fan, M. H.; Van Kirk, E.; Murdoch, W. J. *J. Am. Chem. Soc.* **2010**, *132*, 4259.
 (19) Li, X. Q.; Wen, H. Y.; Dong, H. Q.; Xue, W. M.; Pauletti, G. M.; Cai, X. J.; Xia, W. J.; Shi, D. L.; Li, Y. Y. *Chem. Commun.* **2011**, *47*, 8647.
 (20) Gao, Y.; Kuang, Y.; Guo, Z. F.; Guo, Z. H.; Krauss, I. J.; Xu, B. *J. Am. Chem. Soc.* **2009**, *131*, 13576.
 (21) Li, X. M.; Li, J. Y.; Gao, Y. A.; Kuang, Y.; Shi, J. F.; Xu, B. *J. Am. Chem. Soc.* **2010**, *132*, 17707.
 (22) Cui, H. G.; Webber, M. J.; Stupp, S. I. *Biopolymers* **2010**, *94*, 1.
 (23) Trent, A.; Marullo, R.; Lin, B.; Black, M.; Tirrell, M. *Soft Matter* **2011**, *7*, 9572.
 (24) Pommier, Y. *Nat. Rev. Cancer* **2006**, *6*, 789.
 (25) Thomas, C. J.; Rahier, N. J.; Hecht, S. M. *Bioorg. Med. Chem.* **2004**, *12*, 1585.
 (26) Goux, W. J.; Kopplin, L.; Nguyen, A. D.; Leak, K.; Rutkowsky, M.; Shanmuganandam, V. D.; Sharma, D.; Inouye, H.; Kirschner, D. A. *J. Biol. Chem.* **2004**, *279*, 26868.
 (27) Dubikovskaya, E. A.; Thorne, S. H.; Pillow, T. H.; Contag, C. H.; Wender, P. A. *Proc. Natl. Acad. Sci. U.S.A.* **2008**, *105*, 12128.
 (28) Klug, A. *Philos. Trans. R. Soc., B* **1999**, *354*, 531.
 (29) Huang, Z.; Kang, S.; Banno, M.; Yamaguchi, T.; Lee, D.; Seok, C.; Yashima, E.; Lee, M. *Science* **2012**, *337*, 1521.
 (30) Pizzey, C. L.; Pomerantz, W. C.; Sung, B. J.; Yuwono, V. M.; Gellman, S. H.; Hartgerink, J. D.; Yethiraj, A.; Abbott, N. L. *J. Chem. Phys.* **2008**, *129*.
 (31) Haines-Butterick, L.; Rajagopal, K.; Branco, M.; Salick, D.; Rughani, R.; Pilarz, M.; Lamm, M. S.; Pochan, D. J.; Schneider, J. P. *Proc. Natl. Acad. Sci. U.S.A.* **2007**, *104*, 7791.
 (32) Langeveld-Voss, B. M. W.; Beljonne, D.; Shuai, Z.; Janssen, R. A. J.; Meskers, S. C. J.; Meijer, E. W.; Bredas, J. L. *Adv. Mater.* **1998**, *10*, 1343.
 (33) Aida, T.; Meijer, E. W.; Stupp, S. I. *Science* **2012**, *335*, 813.
 (34) Chourpa, L.; Millot, J. M.; Sockalingum, G. D.; Riou, J. F.; Manfait, M. *Biochim. Biophys. Acta, Gen. Subj.* **1998**, *1379*, 353.
 (35) van Bommel, K. J. C.; Stuart, M. C. A.; Feringa, B. L.; van Esch, J. *Org. Biomol. Chem.* **2005**, *3*, 2917.
 (36) Estrela, J. M.; Ortega, A.; Obrador, E. *Crit. Rev. Clin. Lab. Sci.* **2006**, *43*, 143.